Head-To-Head Review: Nuwellis (NUWE) & Its Peers

Nuwellis (NASDAQ:NUWE) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Nuwellis to similar businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Nuwellis and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1	0	0	0	1.00
Nuwellis Competitors	4288	10570	18345	830	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.17%. Given Nuwellis’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Nuwellis has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Nuwellis and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nuwellis	$9.01 million	-$17.52 million	-0.00
Nuwellis Competitors	$1.89 billion	$136.85 million	12.52

Nuwellis’ competitors have higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Nuwellis has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Nuwellis’ competitors have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.

Insider and Institutional Ownership

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Nuwellis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
Nuwellis Competitors	-304.10%	-178.81%	-22.11%

Summary

Nuwellis competitors beat Nuwellis on 12 of the 13 factors compared.

About Nuwellis

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.